title: gamma-aminobutyric acid mimetic drugs differentially inhibit the dopaminergic response to cocaine.
abstract: Dopaminergic activity in the mesocorticolimbic system is associated with reinforcing properties of psychostimulant drugs. We previously demonstrated that increased gamma-aminobutyric acid (GABA)-ergic activity produced by gamma-vinyl GABA [D,L-4-amino-hex-5-enoic acid (Vigabatrin(R))], an irreversible inhibitor of GABA-transaminase, attenuated cocaine, nicotine, heroin, alcohol, and methamphetamine-induced increases in extracellular nucleus accumbens dopamine as well as behaviors associated with these biochemical changes. In the present study, using in vivo microdialysis techniques, we compared three different strategies to increase GABAergic activity in order to modulate cocaine-induced increase in extracellular dopamine. Our data demonstrate that the anticonvulsant 1-(2-(((diphenylmethylene)amino)oxy)ethyl)-1,2,5, 6-tetrahydro-3-pyridinecarboxylic acid hydrochloride (NNC-711), a GABA uptake inhibitor, dose and time dependently diminished increases in extracellular dopamine following acute cocaine challenge. Furthermore, we demonstrated that cyclized analogue of vigabatrin, a competitive reversible GABA-transaminase inhibitor, is a more potent inhibitor of cocaine-induced dopamine increase than vigabatrin. Our data suggest that in addition to irreversible inhibition of GABA transaminase, inhibition of GABA uptake represent another potentially effective, indirect strategy for the treatment of cocaine abuse.
authors.affiliation: Chemistry Department, Brookhaven National Laboratory, Upton, NY 11973-5000, USA. madina@bnl.gov
authors.forename: M R
authors.initials: MR
authors.lastname: Gerasimov
authors.forename: W K
authors.initials: WK
authors.lastname: Schiffer
authors.forename: J D
authors.initials: JD
authors.lastname: Brodie
authors.forename: I C
authors.initials: IC
authors.lastname: Lennon
authors.forename: S J
authors.initials: SJ
authors.lastname: Taylor
authors.forename: S L
authors.initials: SL
authors.lastname: Dewey
mesh_terms: D000818:Animals; D003042:Cocaine / Q000008:administration & dosage / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D018765:Dopamine Uptake Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D018756:GABA Antagonists / Q000494:pharmacology; D008297:Male; D017551:Microdialysis; D018716:Molecular Mimicry; D009557:Nipecotic Acids / Q000494:pharmacology; D010091:Oximes / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011954:Receptors, Dopamine / Q000187:drug effects / Q000378:metabolism*; D012965:Sodium Chloride; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology
chemical_list: D018765:Dopamine Uptake Inhibitors; D018756:GABA Antagonists; D009557:Nipecotic Acids; D010091:Oximes; D011954:Receptors, Dopamine; C078793:NNC 711; D012965:Sodium Chloride; D005680:gamma-Aminobutyric Acid; D003042:Cocaine